PopularWeight Loss
Semaglutide
Medical weight management
This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.
About Semaglutide
GLP-1 receptor agonist clinically proven for significant weight management results.
How it works
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone. It slows gastric emptying, reduces appetite at the hypothalamic level, and improves insulin sensitivity. Clinical trials show 15-20% body weight loss over 68 weeks.
Clinical evidence
The landmark STEP 1 trial (Wilding et al., NEJM 2021) randomized 1,961 adults with obesity to weekly subcutaneous semaglutide 2.4 mg vs placebo. After 68 weeks, the semaglutide arm achieved a mean weight loss of 14.9% of body weight compared to 2.4% on placebo. The SUSTAIN program demonstrated significant HbA1c reduction in type 2 diabetes, and the SELECT trial (2023) extended the evidence to cardiovascular outcomes — semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease. Compounded semaglutide uses the identical active pharmaceutical ingredient prepared by FDA-registered 503A pharmacies.
Benefits
Semaglutide vs. Ozempic / Wegovy
Same active ingredient. Compounded at an FDA-registered 503A pharmacy.
Dosing
Your prescribing physician determines the right dose, schedule, and how it's administered — based on your goals, medical history, and lab work. Your personalized protocol is provided after your consultation.
Important safety information
+
Possible side effects
Do not use if you have
If you experience severe side effects, call 911 or go to your nearest emergency room.
Frequently asked about Semaglutide
It's the same active ingredient. Ozempic (FDA-approved for diabetes) and Wegovy (FDA-approved for weight loss) are the brand-name versions. Compounded semaglutide is the same molecule, prepared by an FDA-registered 503A compounding pharmacy at significantly lower cost.
References
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · New England Journal of Medicine (2021) · PMID 33567185
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) · New England Journal of Medicine (2023) · PMID 37952131
- Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3) · JAMA (2021) · PMID 33625476
- Rubino D, Abrahamsson N, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 4) · JAMA (2021) · PMID 33755728
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Read more about Semaglutide
Get started today
Ready to start with Semaglutide?
Free assessment. Licensed physicians. Money-back guarantee if not approved.



